EC Number   |
Inhibitors |
Structure |
|---|
   3.4.25.1 | (-)-epigallocatechin-3-gallate |
i.e. EGCG, inhibits the proteasomal chymotrypsin-like activity |
   |
| 3.4.25.1 | (2E)-3-(4-tert-butylphenyl)-1-[4-(4-nitrophenyl)piperazin-1-yl]prop-2-en-1-one |
- |
|
| 3.4.25.1 | (2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,4,5-triethoxybenzoate) |
inhibits 48% of MDA-MB-231 cell proliferation at 0.05 mM |
|
| 3.4.25.1 | (2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,4,5-trihydroxybenzoate) |
- |
|
| 3.4.25.1 | (2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-diethoxybenzoate) |
70-79% inhibition in MDA-MB-231 cells at 0.025-0.050 mM |
|
| 3.4.25.1 | (2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-dihydroxybenzoate) |
- |
|
| 3.4.25.1 | (acetato-kappaO)[2,4-diiodo-6-({[(pyridin-2-yl-kappaN)methyl]amino-kappaN}methyl)phenolato-kappaO]copper |
a copper complex, causes selective 20S proteasomal inhibition and apoptosis induction in several lines of cancer cells |
|
| 3.4.25.1 | 1-[1-(1-[(2,4-dioxoimidazolidin-1-ylimino)-methyl]-2-phenyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl]-2-(1H-indol) |
i.e. S-2209, potently inhibits chymotrypsin-like proteasome activity of the human 20S proteasome. S-2209 targets NFkappaB activity, overview. S-2209 inhibits cell growth and induces apoptosis in human multiple myeloma cells, mechanisms, overview |
|
| 3.4.25.1 | 1-[1-(1-[(2,4-dioxoimidazolidin-1-ylimino)-methyl]-2-phenyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl]-2-(1H-indol) |
i.e. S-2209, targets NFkappaB activity, overview |
|
| 3.4.25.1 | 2-(2-bromo-4-tert-butylphenoxy)-1-[4-(4-nitrophenyl)piperazin-1-yl]ethanone |
- |
|
